{"id":2416,"date":"2012-04-03T00:00:27","date_gmt":"2012-04-03T04:00:27","guid":{"rendered":"https:\/\/www.bu.edu\/neidl\/?p=2416"},"modified":"2012-06-28T17:09:49","modified_gmt":"2012-06-28T21:09:49","slug":"biosafety-level-2-research-to-start","status":"publish","type":"post","link":"https:\/\/www.bu.edu\/neidl\/2012\/04\/biosafety-level-2-research-to-start\/","title":{"rendered":"BSL-2 Research to Start at BU Biolab"},"content":{"rendered":"<p><strong>Released:<\/strong> April 4, 2012<br \/>\n<strong>Contact:<\/strong> Ellen Berlin, 617-520-7115 or Tom Testa, 617-959-3887<\/p>\n<p>(Boston) \u2014 Boston University researchers are moving into the National Emerging Infectious Diseases Laboratories (NEIDL) at Boston University this week and will begin conducting BSL-2 research.\u00a0 They will conduct tuberculosis (TB) research that has been approved for the BSL-2 laboratories.<\/p>\n<p>The funding for these BSL-2 research grants totals more than $4.5 million and 15 researchers have been hired to work on these tuberculosis research projects.<\/p>\n<p>James Galagan, PhD, Associate Professor, Biomedical Engineering &amp; Microbiology and Associate Director, Systems Biology, National Emerging Infectious Diseases Laboratories, leads the team studying a non-pathogenic close relative of the organism that causes TB, called <em>Mycobacterium smegmatis<\/em>.\u00a0 By studying the non-pathogenic <em>M. smegmatis<\/em>, the lab researchers hope to gain insight into how key gene control mechanisms work.<\/p>\n<p>Igor Kramnik, MD, PhD, Associate Professor of Medicine and Director of the Aerobiology Core leads the team studying the mechanisms of host resistance to bacteria by using non-pathogenic vaccine strain BCG to better understand how it stimulates immunity and how to improve vaccine potency and safety.<\/p>\n<p>\u201cWe are pleased that BSL-2 research is starting in the NEIDL. It is noteworthy that these researchers will be conducting important public health research on a disease that affects nearly one-third of the world\u2019s population,\u201d said John Murphy, PhD, NEIDL Interim Director.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Initial research to focus on tuberculosis<\/p>\n","protected":false},"author":1129,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[3075,452],"tags":[],"_links":{"self":[{"href":"https:\/\/www.bu.edu\/neidl\/wp-json\/wp\/v2\/posts\/2416"}],"collection":[{"href":"https:\/\/www.bu.edu\/neidl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bu.edu\/neidl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/neidl\/wp-json\/wp\/v2\/users\/1129"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/neidl\/wp-json\/wp\/v2\/comments?post=2416"}],"version-history":[{"count":10,"href":"https:\/\/www.bu.edu\/neidl\/wp-json\/wp\/v2\/posts\/2416\/revisions"}],"predecessor-version":[{"id":3001,"href":"https:\/\/www.bu.edu\/neidl\/wp-json\/wp\/v2\/posts\/2416\/revisions\/3001"}],"wp:attachment":[{"href":"https:\/\/www.bu.edu\/neidl\/wp-json\/wp\/v2\/media?parent=2416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bu.edu\/neidl\/wp-json\/wp\/v2\/categories?post=2416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bu.edu\/neidl\/wp-json\/wp\/v2\/tags?post=2416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}